Drug Trial Radar · NCT04820049
F573 Ia Clinical Trial
Last checked: Nov 19, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Feb 8, 2021
Primary completion
Aug 2, 2022
Study completion Nov 6, 2022
Sponsor
- Lead sponsor
- Beijing Continent Pharmaceutical Co, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Tolerance and PK study of F573
Conditions
- Tolerance
- Pharmacokinetic
Interventions
F573Drug
F573 for injection
PlaceboOther
Water for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTD of F573 in health peopleTime frame: up to 7 days
- Cmax of F573 in health peopleTime frame: up to 7 days
- Tmax of F573 in health peopleTime frame: up to 7 days
- t1/2 of F573 in health peopleTime frame: up to 7 days
- AUC of F573 in health peopleTime frame: up to 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.